Efficacy of antidepressants in treating the negative symptoms of chronic schizophrenia: meta-analysis

被引:158
作者
Singh, Surendra P. [1 ,2 ]
Singh, Vidhi
Kar, Nilamadhab [1 ]
Chan, Kelvin [3 ,4 ]
机构
[1] Wolverhampton City Primary Care Trust, Mental Hlth Directorate, Wolverhampton WV10 9TH, W Midlands, England
[2] Wolverhampton Univ, Sch Hlth & Wellbeing, Wolverhampton WV1 1DJ, W Midlands, England
[3] Wolverhampton Univ, Res Inst Healthcare Sci, Wolverhampton WV1 1DJ, W Midlands, England
[4] Wolverhampton Univ, Dept Pharm, Wolverhampton WV1 1DJ, W Midlands, England
关键词
SEROTONIN REUPTAKE INHIBITOR; PLACEBO-CONTROLLED TRIAL; INDUCED WEIGHT-GAIN; ADD-ON THERAPY; DOUBLE-BLIND; MIRTAZAPINE ADD; FLUOXETINE; ANTIPSYCHOTICS; ANTAGONIST; AUGMENTATION;
D O I
10.1192/bjp.bp.109.067710
中图分类号
R749 [精神病学];
学科分类号
100205 ;
摘要
Background Treatment of negative symptoms in chronic schizophrenia continues to be a major clinical issue. Aims To analyse the efficacy of add-on antidepressants for the treatment of negative symptoms of chronic schizophrenia. Method Systematic review and meta-analysis of randomised controlled trials comparing the effect of antidepressants and placebo on the negative symptoms of chronic schizophrenia, measured through standardised rating scales. Outcome was measured as standardised mean difference between end-of-trial and baseline scores of negative symptoms. Results There were 23 trials from 22 publications (n=819). The antidepressants involved were selective serotonin reuptake inhibitors, mirtazapine, reboxetine, mianserin, trazodone and ritanserin; trials on other antidepressants were not available. The overall standardised mean difference was moderate (-0.48) in favour of antidepressants and subgroup analysis revealed significant responses for fluoxetine, trazodone and ritanserin. Conclusions Antidepressants along with antipsychotics are more effective in treating the negative symptoms of schizophrenia than antipsychotics alone.
引用
收藏
页码:174 / 179
页数:6
相关论文
共 45 条
[1]   Effect of ritanserin, a 5HT2A/2C antagonist, on negative symptoms of schizophrenia: A double-blind randomized placebo-controlled study [J].
Akhondzadeh, Shahin ;
Malek-Hosseini, Mojgan ;
Ghoreishi, Aboulfazl ;
Raznahan, Maedeh ;
Rezazadeh, Shams-Ali .
PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY, 2008, 32 (08) :1879-1883
[2]   Fluoxetine as an adjunct to conventional antipsychotic treatment of schizophrenia patients with residual symptoms [J].
Arango, C ;
Kirkpatrick, B ;
Buchanan, RW .
JOURNAL OF NERVOUS AND MENTAL DISEASE, 2000, 188 (01) :50-53
[3]   Efficacy and tolerability of tricyclic antidepressants and SSRIs compared with placebo for treatment of depression in primary care: A meta-analysis [J].
Arroll, B ;
Macgillivray, S ;
Ogston, S ;
Reid, I ;
Sullivan, F ;
Williams, B ;
Crombie, I .
ANNALS OF FAMILY MEDICINE, 2005, 3 (05) :449-456
[4]   Efficacy of mirtazapine add on therapy to haloperidol in the treatment of the negative symptoms of schizophrenia: a double-blind randomized placebo-controlled study [J].
Berk, M ;
Ichim, C ;
Brook, S .
INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY, 2001, 16 (02) :87-92
[5]   Mirtazapine add-on therapy in the treatment of schizophrenia with atypical antipsychotics: a double-blind, randomised, placebo-controlled clinical trial [J].
Berk, Michael ;
Gama, Clarissa S. ;
Sundram, Suresh ;
Hustig, Harry ;
Koopowitz, Les ;
D'Souza, Russell ;
Malloy, Hamish ;
Rowland, Cate ;
Monkhouse, Alison ;
Monkhouse, Andrew ;
Bole, Fiona ;
Sathiyamoorthy, Sumathy ;
Piskulic, Danijela ;
Dodd, Seetal .
HUMAN PSYCHOPHARMACOLOGY-CLINICAL AND EXPERIMENTAL, 2009, 24 (03) :233-238
[6]  
Buchanan RW, 1996, AM J PSYCHIAT, V153, P1625
[7]   Treatment of weight gain with fluoxetine in olanzapine-treated schizophrenic outpatients [J].
Bustillo, JR ;
Lauriello, J ;
Parker, K ;
Hammond, R ;
Rowland, L ;
Bogenschutz, M ;
Keith, S .
NEUROPSYCHOPHARMACOLOGY, 2003, 28 (03) :527-529
[8]  
Cohen J., 1988, Statistical power analysis for the behavioral sciences, VSecond
[9]  
DECINA P, 1994, HOSP COMMUNITY PSYCH, V45, P1220
[10]   RITANSERIN, A SELECTIVE 5-HT(2/1C) ANTAGONIST, AND NEGATIVE SYMPTOMS IN SCHIZOPHRENIA - A PLACEBO-CONTROLLED DOUBLE-BLIND TRIAL [J].
DUINKERKE, SJ ;
BOTTER, PA ;
JANSEN, AAI ;
VANDONGEN, PAM ;
VANHAAFTEN, AJ ;
BOOM, AJ ;
VANLAARHOVEN, JHM ;
BUSARD, HLSM .
BRITISH JOURNAL OF PSYCHIATRY, 1993, 163 :451-455